For the quarter ending 2026-03-31, MIRA had -$1,531,890 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,150,152 | -5,983,321 | -1,137,673 | -3,321,491 |
| Stock-based compensation expense | 107,590 | 4,557,949 | 390,840 | 1,364,378 |
| Unrealized loss on short-term investments | - | -211,268 | 176,056 | - |
| Loss from equity method investments | -91,582 | - | - | - |
| Prepaid expenses | -6,397 | -33,789 | -40,468 | 47,674 |
| Other receivables | - | - | - | 0 |
| Trade accounts payable and accrued expenses | -95,195 | 45,278 | -214,533 | -424,891 |
| Related party accrued interest and accrued compensation | 161,505 | - | - | - |
| Net cash used in operating activities | -1,201,283 | -1,135,037 | -1,096,954 | -2,429,678 |
| Offering costs | - | 158,421 | 112,569 | 21,480 |
| Proceeds from related party | - | 572,865 | - | - |
| Proceeds from stock option exercises | - | - | 297,792 | - |
| Proceeds from common stock option exercises | - | 888,282 | - | - |
| Proceeds from sale of common stock | - | 3,835,485 | 2,822,795 | 348,702 |
| Repayment of advance payable to related party | 330,607 | - | - | - |
| Net cash (used) provided by financing activities | -330,607 | 4,840,419 | 3,008,018 | 327,222 |
| Net decrease in cash | -1,531,890 | 3,705,382 | 1,911,064 | -2,102,456 |
| Cash, beginning of period | 6,346,921 | 2,641,539 | 2,832,931 | - |
| Cash, end of period | 4,815,031 | 6,346,921 | 2,641,539 | - |
MIRA PHARMACEUTICALS, INC. (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA)